Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

University of Glasgow

Status and phase: Unknown; Phase 2

Conditions: Asthma

Treatments: Drug: Placebo; Drug: Bosentan; Drug: Ambrisentan

Study type: Interventional

Funder types: Other

Identifiers

NCT01617746

AR012

Details and patient eligibility

About

The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Full description

Endothelin 1 may have a role in the development of acute airway narrowing in asthma. Blockade of the endothelin system may thereby protect against airway narrowing. Two receptors exist for endothelin 1, Endothelin A & B. Both can be blocked by Bosentan, and the A receptor by ambrisentan. Both medications are currently in use for the treatment of pulmonary arterial hypertension. The investigators will endeavour to examine the potential role of endothelin 1 in the development of airway narrowing in asthma through blockade of the endothelin receptors A&B through the use of bosentan and ambrisentan.

Enrollment: 18 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Physician diagnosis of asthma confirmed objectively by airway hyperactivity to methacholine (as determined by a ≥ 20% drop in FEV at a methacholine dose of ≤ 8mg/ml after β-agonist withdrawal as per ATS guidelines)
2. Age range 18-60 years
3. FEV1 ≥ 60% predicted
4. Duration of asthma > 6 months and on stable medication for 4 weeks
5. Prescribed and compliant with inhaled corticosteroid up to a maximum of 2000mcg beclomethasone or equivalent
6. No history of previous regular smoking and current non-smoker

Exclusion criteria

1. Unstable asthma; defined as the presence of 1 or more of the following events in the month prior to study [Emergency/'out of hours' visit to GP for asthma exacerbation; GP visit to patient at home for asthma exacerbation or A & E/hospital admission for asthma exacerbation]

2. Treatment with oral corticosteroids in the past month

3. Need for maintenance oral corticosteroid therapy

4. Pregnancy or planning to become pregnant over course of study and up to one month after

5. Excessive risk of hepatotoxicity from endothelin receptor antagonists;

   • Alcohol excess (defined as regular consumption above government daily recommend limits; currently defined as 28 units per wk for men, 21 units per week for women)
   • Previous intravenous drug use
   • Current or known history of liver disease (with the exception of Gilberts disease and gallstones)
   • Chronic hepatitis (either viral (e.g. hepatitis B or C) or autoimmune)
   • Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST) greater than the upper limit of normal at screening

6. Anaemia (defined as haemoglobin below the lower reference range for sex) at screening

7. Renal failure (defined as eGFR less than 50 mL/minute/1.73 m2) at screening

8. Known HIV positivity

9. History of inability to tolerate bosentan or ambrisentan

10. Significant medical conditions other than asthma felt by investigator to preclude participation in study. This could be either in patients best interest or due to potential to significantly alter responses to medication and hence alter power of clinical trial (examples include; significant heart failure (NYHA grades II-IV), diabetes mellitus, bronchiectasis or haematological malignancy).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

18 participants in 3 patient groups, including a placebo group

Ambrisentan

Experimental group

Description:

5mg od ambrisentan

Treatment:

Drug: Ambrisentan

Bosentan

Experimental group

Description:

62.5mg bosentan

Treatment:

Drug: Bosentan

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo